share_log

賽生藥業:有關聯席公司秘書資格的最新情況及聯席公司秘書辭任

SCICLONE PHARMA: UPDATE ON QUALIFICATIONS OF JOINT COMPANY SECRETARY AND RESIGNATION OF JOINT COMPANY SECRETARY

香港交易所 ·  Mar 28 00:01
Summary by Moomoo AI
賽生藥業控股有限公司(「賽生藥業」)於2024年3月28日宣佈,潘蓉容女士已獲香港聯合交易所有限公司(「聯交所」)確認符合《證券上市規則》擔任公司秘書的資格,因此不再需要進一步豁免,將正式擔任公司秘書。同時,陳倩敏女士已辭任聯席公司秘書一職,並於同日生效。陳女士確認與董事會無意見分歧,也無需向股東或聯交所報告的相關辭任事宜。賽生藥業董事會對陳女士在任期間的貢獻表示感謝。
賽生藥業控股有限公司(「賽生藥業」)於2024年3月28日宣佈,潘蓉容女士已獲香港聯合交易所有限公司(「聯交所」)確認符合《證券上市規則》擔任公司秘書的資格,因此不再需要進一步豁免,將正式擔任公司秘書。同時,陳倩敏女士已辭任聯席公司秘書一職,並於同日生效。陳女士確認與董事會無意見分歧,也無需向股東或聯交所報告的相關辭任事宜。賽生藥業董事會對陳女士在任期間的貢獻表示感謝。
Sai Sang Pharmaceutical Holdings Limited (“Sai Sai Pharma”) announced on 28 March 2024 that Ms. Pan has been confirmed as Company Secretary by the United Stock Exchange of Hong Kong Limited (the “Exchange”) to serve as Company Secretary under the Securities Listing Rules and will no longer require further exemptions and will be formally acting as a Company Secretary Books. At the same time, Ms. CHAN Sian Min has resigned as Joint Company Secretary effective the same day. MS. CHAN CONFIRMS THAT THERE IS NO DISAGREEMENT WITH THE BOARD OF DIRECTORS AND THAT THERE IS NO NEED TO REPORT RESIGNATIONS TO SHAREHOLDERS OR THE EXCHANGE. The Board of Directors of Sai Sang Pharmaceuticals expressed its gratitude for Ms. Chan's contributions during her tenure.
Sai Sang Pharmaceutical Holdings Limited (“Sai Sai Pharma”) announced on 28 March 2024 that Ms. Pan has been confirmed as Company Secretary by the United Stock Exchange of Hong Kong Limited (the “Exchange”) to serve as Company Secretary under the Securities Listing Rules and will no longer require further exemptions and will be formally acting as a Company Secretary Books. At the same time, Ms. CHAN Sian Min has resigned as Joint Company Secretary effective the same day. MS. CHAN CONFIRMS THAT THERE IS NO DISAGREEMENT WITH THE BOARD OF DIRECTORS AND THAT THERE IS NO NEED TO REPORT RESIGNATIONS TO SHAREHOLDERS OR THE EXCHANGE. The Board of Directors of Sai Sang Pharmaceuticals expressed its gratitude for Ms. Chan's contributions during her tenure.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more